SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients : Effects of monotherapy with rimonabant, the first selective CB(1) receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes

OBJECTIVE—The purpose of this study was to assess the glucose-lowering efficacy and safety of rimonabant monotherapy in drug-naive type 2 diabetic patients. RESEARCH DESIGN AND METHODS—The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients (SERENADE) was a 6-month, randomized, doub...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Hollander, Priscilla, Chevalier, Soazig, Iranmanesh, Ali
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Emerging Treatments and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571069/
https://www.ncbi.nlm.nih.gov/pubmed/18678611
http://dx.doi.org/10.2337/dc08-0386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571069/
https://www.ncbi.nlm.nih.gov/pubmed/18678611
http://dx.doi.org/10.2337/dc08-0386

Ejemplares similares